Frontiers in Molecular Neuroscience (Jun 2022)
Iron Neurotoxicity and Protection by Deferoxamine in Intracerebral Hemorrhage
- Zhe Li,
- Zhe Li,
- Zhe Li,
- Yang Liu,
- Yang Liu,
- Yang Liu,
- Ruixue Wei,
- Ruixue Wei,
- Ruixue Wei,
- Suliman Khan,
- Suliman Khan,
- Suliman Khan,
- Ruiyi Zhang,
- Ruiyi Zhang,
- Ruiyi Zhang,
- Yan Zhang,
- Yan Zhang,
- Yan Zhang,
- Voon Wee Yong,
- Mengzhou Xue,
- Mengzhou Xue,
- Mengzhou Xue
Affiliations
- Zhe Li
- Department of Cerebrovascular Diseases, The Second Affiliated Hospital of Zhengzhou University, Zhengzhou, China
- Zhe Li
- Academy of Medical Science, Zhengzhou University, Zhengzhou, China
- Zhe Li
- Henan Medical Key Laboratory of Translational Cerebrovascular Diseases, Zhengzhou, China
- Yang Liu
- Department of Cerebrovascular Diseases, The Second Affiliated Hospital of Zhengzhou University, Zhengzhou, China
- Yang Liu
- Academy of Medical Science, Zhengzhou University, Zhengzhou, China
- Yang Liu
- Henan Medical Key Laboratory of Translational Cerebrovascular Diseases, Zhengzhou, China
- Ruixue Wei
- Department of Cerebrovascular Diseases, The Second Affiliated Hospital of Zhengzhou University, Zhengzhou, China
- Ruixue Wei
- Academy of Medical Science, Zhengzhou University, Zhengzhou, China
- Ruixue Wei
- Henan Medical Key Laboratory of Translational Cerebrovascular Diseases, Zhengzhou, China
- Suliman Khan
- Department of Cerebrovascular Diseases, The Second Affiliated Hospital of Zhengzhou University, Zhengzhou, China
- Suliman Khan
- Academy of Medical Science, Zhengzhou University, Zhengzhou, China
- Suliman Khan
- Henan Medical Key Laboratory of Translational Cerebrovascular Diseases, Zhengzhou, China
- Ruiyi Zhang
- Department of Cerebrovascular Diseases, The Second Affiliated Hospital of Zhengzhou University, Zhengzhou, China
- Ruiyi Zhang
- Academy of Medical Science, Zhengzhou University, Zhengzhou, China
- Ruiyi Zhang
- Henan Medical Key Laboratory of Translational Cerebrovascular Diseases, Zhengzhou, China
- Yan Zhang
- Department of Cerebrovascular Diseases, The Second Affiliated Hospital of Zhengzhou University, Zhengzhou, China
- Yan Zhang
- Academy of Medical Science, Zhengzhou University, Zhengzhou, China
- Yan Zhang
- Henan Medical Key Laboratory of Translational Cerebrovascular Diseases, Zhengzhou, China
- Voon Wee Yong
- Department of Clinical Neurosciences, Hotchkiss Brain Institute, University of Calgary, Calgary, AB, Canada
- Mengzhou Xue
- Department of Cerebrovascular Diseases, The Second Affiliated Hospital of Zhengzhou University, Zhengzhou, China
- Mengzhou Xue
- Academy of Medical Science, Zhengzhou University, Zhengzhou, China
- Mengzhou Xue
- Henan Medical Key Laboratory of Translational Cerebrovascular Diseases, Zhengzhou, China
- DOI
- https://doi.org/10.3389/fnmol.2022.927334
- Journal volume & issue
-
Vol. 15
Abstract
Intracerebral hemorrhage (ICH) is a subtype of stroke that is characterized by high morbidity and mortality, for which clinical outcome remains poor. An extensive literature indicates that the release of ferrous iron from ruptured erythrocytes in the hematoma is a key pathogenic factor in ICH-induced brain injury. Deferoxamine is an FDA-approved iron chelator that has the capacity to penetrate the blood-brain barrier after systemic administration and binds to iron. Previous animal studies have shown that deferoxamine attenuates ICH-induced brain edema, neuronal death, and neurological deficits. This review summarizes recent progress of the mechanisms by which deferoxamine may alleviate ICH and discusses further studies on its clinical utility.
Keywords
